

MORGAN & FINNEGAN, L.L.P.

A Registered Limited Liability Partnership

345 PARK AVENUE

NEW YORK, NEW YORK 10154-0053

Tel.: (212) 758-4800

Telex 421792

Facsimile: (212) 751-6849

FAX COVER SHEET

To: Examiner S. Devi
Company: USPTO
Phone #:
Fax #: (703) 308-4242

From: Darryl H. Steensma
Phone #: (212) 415-8565

Client: 1758
Matter: 4036US2

Date: January 29, 2001
Pages: 4 (plus this cover sheet)

Confirm:

Comments: According to your request, transmitted herewith is a courtesy copy of the Response filed October 16, 2000.

Sincerely,
Darryl H. Steensma

THE DOCUMENT(S) ACCOMPANYING THIS FACSIMILE TRANSMISSION CONTAINS INFORMATION FROM THE LAW FIRM OF MORGAN & FINNEGAN, LLP WHICH IS CONFIDENTIAL AND/OR LEGALLY PRIVILEGED. THE INFORMATION IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY NAMED ON THIS TRANSMISSION SHEET. IF YOU ARE NOT THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY DISCLOSURE, COPYING, DISTRIBUTION OR THE TAKING OF ANY ACTION IN RELIANCE ON THE CONTENTS OF THIS FAXED INFORMATION IS STRICTLY PROHIBITED, AND THE DOCUMENT(S) SHOULD BE RETURNED TO THIS FIRM IMMEDIATELY. IF YOU HAVE RECEIVED THIS FACSIMILE IN ERROR, PLEASE NOTIFY US BY TELEPHONE IMMEDIATELY SO THAT WE CAN ARRANGE FOR THE RETURN OF THE ORIGINAL DOCUMENTS AT NO COST TO YOU.

Received 10-19-00

Box AF

PATENT

Docket No. 1758-4036US2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : MINETTI, C. et al.

Serial No : 09/120,044

Art Unit : 1645

Filed : July 21, 1998

Examiner : S. Devi

For: : MODIFIED IMMUNOGENIC PNEUMOLYSIN
COMPOSITIONS AS VACCINES**AMENDMENT AND RESPONSE TO OFFICIAL ACTION**Box AF
COMMISSION FOR PATENTS
Washington, D.C. 20231

Sir:

O.K. to enter.

In response to the Official Action mailed July 28, 2000, applicants present the following amendment and remarks. Claims 1-34 are pending in the application. Claims 8-11, 16-21 and 27-30 were withdrawn from consideration. Claims 12-15 were allowed and claims 1-7, 22-26, and 31-34 were rejected. Claims 1-7, 22-26 and 31-34 are presented for review and reconsideration on the merits. Applicants include a Notice of Appeal concerning the July 28, 2000 final rejection.

AMENDMENT

Please amend the claims as follows:

- E1
1. (twice amended) A modified refoldable pneumolysin polypeptide having attenuated hemolytic activity comprising an amino acid sequence of type 14 pneumolysin wherein (at least one amino acid in the region comprising amino acid residues 1 to 257 of SEQ ID NO: 3[, and besides a substitution of threonine for isoleucine at amino acid 172,] is substituted, with the proviso that the substitution is not solely a substitution of isoleucine for threonine at
- N/M